Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

CJC-1295 No DAC Dosing Protocol: 5 mg Vial — Pulsatile GHRH Dosing Guide

CJC-1295 without DAC (Modified GRF 1-29) protocol — the pulsatile GHRH analogue for 2–3x daily injection alongside GHRPs.

Quickstart highlights

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a 29-amino acid GHRH analogue with four amino acid substitutions (Ala8, Glu15, Ala18, Arg26) that improve receptor affinity and proteolytic stability over native GHRH while maintaining a physiological 30-minute half-life.

  • Concentration: 2 mg/mL (5 mg vial + 2.5 mL bacteriostatic water).
  • At 2 mg/mL: 200 µg = 10 units, 300 µg = 15 units per injection.
  • Half-life: ~30 minutes — inject simultaneously with GHRP (ipamorelin, GHRP-2) for synergistic GH release.
  • Can be mixed with ipamorelin or GHRP-2 in the same syringe immediately before injection.
  • One 5 mg vial provides ~17 doses at 300 µg — approximately 5–6 days at 3x daily.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4200101–2x daily with GHRP200 µg — 10 units; pair with ipamorelin or GHRP-2 (200 µg) in same syringe or adjacent site
5-12300152–3x daily with GHRP300 µg — 15 units; 3x daily protocol produces maximum pulsatile GH output

Reconstitution steps

  1. Draw 2.5 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until powder dissolves; do not shake.
  3. Final concentration: 2 mg/mL (2,000 µg/mL). At 2 mg/mL: 200 µg = 10 units, 300 µg = 15 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

4-week plan

  • 2 vials
  • 28 syringes
  • 5 mL bac water
  • 28 alcohol swabs

8-week plan

  • 4 vials
  • 56 syringes
  • 10 mL bac water
  • 56 alcohol swabs

12-week plan

  • 5 vials
  • 84 syringes
  • 13 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Achieve maximal pulsatile GH secretion through the precise co-injection of CJC-1295 No DAC (GHRH) and a GHRP (ipamorelin or GHRP-2) 2–3x daily, mimicking the natural GHRH + ghrelin synergy that drives physiological GH pulses.

Cycle length: 12 weeks on.

Off-cycle: 4–6 weeks off; measure IGF-1 before resuming.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. At 300 µg 3x daily: one 5 mg vial provides ~17 doses — approximately 5–6 days; plan 15+ vials per 12-week cycle.

Injection & tracking tips

  • CJC-1295 No DAC has a 30-minute half-life — timing with the GHRP injection is critical; inject within 5 minutes of each other.
  • Can be mixed in the same syringe as ipamorelin or GHRP-2 for a single injection — stable when mixed immediately before use; do not pre-mix and store.
  • Inject in fasted state (2+ hours post-meal); food-driven insulin blunts GH response to the peptide combination.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure IGF-1 at baseline, 6 weeks, and 12 weeks.
  • Track sleep quality nightly (subjective 0–10 or wearable deep sleep data).
  • Log body fat percentage monthly via InBody or DEXA.
Log your cycle in the calculator →

How this works & references

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a 29-amino acid GHRH analogue with four amino acid substitutions (Ala8, Glu15, Ala18, Arg26) that improve receptor affinity and proteolytic stability over native GHRH while maintaining a physiological 30-minute half-life. This allows precise, pulsatile GHRH delivery matched to each GHRP injection. The combination of Mod-GRF + ipamorelin or GHRP-2 produces GH pulses 2–4x greater than either peptide alone, as they act through complementary pituitary receptor pathways (GHRH-R and GHSR-1a).

Frequently asked questions

What is the key difference between CJC-1295 DAC and CJC-1295 No DAC?
No DAC has a 30-minute half-life, requiring 2–3 daily injections to maintain GHRH signaling — but produces precisely timed, physiological GH pulses. DAC binds albumin for a 7-day half-life, allowing once-weekly dosing but producing a continuous rather than pulsatile GH elevation. Many practitioners prefer No DAC + GHRP for more physiological GH pulsatility.
Can I mix CJC-1295 No DAC with ipamorelin in one syringe?
Yes — this is standard practice. Draw 15 units of ipamorelin (300 µg) followed by 15 units of CJC-1295 No DAC (300 µg) into the same U-100 syringe for a combined 30-unit injection. Mix immediately before use; do not pre-mix and refrigerate.
Why does the No DAC formulation produce more physiological GH pulsatility?
Natural GH secretion occurs in distinct pulses driven by hypothalamic GHRH and ghrelin surges every 3–4 hours. CJC-1295 No DAC's 30-minute half-life mimics this pulse pattern when injected 2–3x daily with a GHRP. The DAC formulation's 7-day bioavailability creates continuous GH elevation, which is less physiological.
Is CJC-1295 No DAC the same as Mod-GRF 1-29?
Yes — CJC-1295 No DAC, Modified GRF 1-29 (Mod-GRF), and GRF(1-29) NH2 with four substitutions are all names for the same peptide. The term 'CJC-1295' originally referred to the DAC version in the published Teichman trial; the No DAC version co-opted the name in the research peptide market.
How long before results are noticeable with the No DAC + ipamorelin combination?
Sleep quality improvements: 2–4 weeks. Measurable IGF-1 increases: 4–6 weeks. Body composition changes (fat loss, muscle fullness): 8–12 weeks of consistent 2–3x daily dosing.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.